Results 151 to 160 of about 3,531,408 (290)
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Xiaoting Liu +13 more
wiley +1 more source
Single‐cell RNA editing analysis identifies ADAR1 as a regulator of dysfunctional T cell states in colorectal cancer. Elevated ADAR1 activity promotes T cell exhaustion and impairs antitumor immunity partly through TGF‐β‐SMAD signaling, contributing to anti‐PD‐1 resistance and highlighting T cell ADAR1 as a potential therapeutic target and biomarker ...
Da Kang +10 more
wiley +1 more source
ACSS2 is required for colorectal cancer progression and a druggable target for colorectal cancer treatment. [PDF]
Wang L +10 more
europepmc +1 more source
This study shows that in glioma stem cells (GSCs), RBM12 recruits ALKBH5 to remove m6A from SLC7A5 transcripts, thereby enhancing mRNA stability, which elevates large neutral amino acid (LNAA) levels and activates mTORC1, promoting GSC proliferation, self‐renewal, and tumor growth.
Hong Lei +18 more
wiley +1 more source
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu +13 more
wiley +1 more source
Targeting colorectal cancer and T‑cell metabolism for the treatment of colorectal cancer (Review). [PDF]
Yu Q, Luan P, Liang J, Wang L.
europepmc +1 more source
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo +16 more
wiley +1 more source
Host-Microbe Mechanisms of Fusobacterium nucleatum in Colorectal Cancer. [PDF]
Leite HLA, Lopes FF.
europepmc +1 more source
The HILA nanoplatform integrates HMnO2, LOX, and ICG to orchestrate multimodal therapy (starvation, chemodynamic, photodynamic, and photothermal) for achieving efficient colon cancer eradication. The established HMnO2‐LOX catalytic cycle continuously consumes lactate, acidifys microenvironment, relieves hypoxia, and generats reactive oxygen species ...
Yu‐E. Wang +11 more
wiley +1 more source
National cohort study on postoperative risks after surgery for submucosal invasive colorectal cancer
Background: The decision to perform surgery for patients with T1 colorectal cancer hinges on the estimated risk of lymph node metastasis, residual tumour and risks of surgery.
Dutch T1 Colorectal Cancer Working Group
core

